ArticleFrontiers in medicine2026
Case Report: Individualized management of tuberous sclerosis complex-associated lymphangioleiomyomatosis.
Article in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Tuberous sclerosis complex-associated lymphangioleiomyomatosis (TSC-LAM) is a rare systemic disorder characterized by smooth muscle-like cell proliferation, leading to cystic lung destruction, predominantly affecting women of reproductive age. We report a female patient in her mid-30s who presented with recurrent spontaneous pneumothoraces temporally associated with menstruation, diffuse bilateral pulmonary cysts on high-resolution computed tomography, bilateral renal angiomyolipomas, and facial angiofibromas. Genetic testing confirmed TSC-LAM. The patient was initiated on sirolimus (1 mg/day) with therapeutic drug monitoring to maintain trough levels within the target range. Regular follow-up included pulmonary function tests, serial imaging, and genetic counseling with cascade screening for offspring. After treatment, the disease remained clinically stable without significant adverse effects; imaging demonstrated no progression of pulmonary cysts and a reduction in renal angiomyolipoma volume. This case underscores the importance of early recognition, individualized sirolimus dosing to balance efficacy and toxicity, and systematic family screening for early detection and prevention of disease transmission in this heritable condition.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.